Article Text

Download PDFPDF
Disease progression of Takayasu arteritis in two patients treated with tocilizumab
  1. Catalina Sanchez-Alvarez,
  2. Matthew Koster,
  3. Ali Duarte-García,
  4. Kenneth J Warrington
  1. Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Catalina Sanchez-Alvarez, Department of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA ; sanchez.catalina{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


In recent years there has been growing interest in the use of tocilizumab for the treatment of large vessel vasculitis, particularly giant cell arteritis.1 Nakaoka et al recently suggested that tocilizumab may be of therapeutic benefit in patients with relapsing Takayasu arteritis (TAK).2 In this journal, a case of aortic ulceration in a patient with TAK while on tocilizumab was described.3 We report two additional patients who had disease progression despite tocilizumab therapy.

Case 1

A 44-year-old woman with a 20-year history of seropositive rheumatoid arthritis in clinical remission on adalimumab presented with new-onset right upper extremity claudication. A diagnosis of TAK was made after angiography demonstrated arterial thickening of the aorta and arch branches with multifocal narrowing of the subclavian and common carotid arteries. …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors All authors were involved in the preparation of the manuscript and have approved the manuscript and this submission.

  • Conflict of interest None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.